iBio, Inc. Common Stock (NYSE MKT:IBIO) — Market Cap & Net Worth
Market Cap & Net Worth: iBio, Inc. Common Stock (IBIO)
iBio, Inc. Common Stock (NYSE MKT:IBIO) has a market capitalization of $24.96 Million ($24.96 Million) as of July 7, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #24355 globally and #5173 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying iBio, Inc. Common Stock's stock price $1.20 by its total outstanding shares 22487308 (22.49 Million). Review IBIO liabilities breakdown to assess the company's total debt and financial obligations.
iBio, Inc. Common Stock Market Cap History: 2015 to 2025
iBio, Inc. Common Stock's market capitalization history from 2015 to 2025. Data shows change from $62.96 Billion to $26.98 Million (-54.45% CAGR).
Index Memberships
iBio, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.00% | #700 of 976 |
|
NASDAQ Composite
IXIC
|
$40.68 Trillion | 0.00% | #2303 of 3165 |
Weight: iBio, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
iBio, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how iBio, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
67.46x
iBio, Inc. Common Stock's market cap is 67.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $44.41 Billion | $948.00K | -$9.76 Million | 46848.56x | N/A |
| 2017 | $19.91 Billion | $394.00K | -$14.53 Million | 50539.37x | N/A |
| 2018 | $8.47 Billion | $444.00K | -$16.11 Million | 19078.76x | N/A |
| 2019 | $2.80 Billion | $2.02 Million | -$17.59 Million | 1387.35x | N/A |
| 2020 | $11.81 Billion | $1.64 Million | -$16.44 Million | 7207.47x | N/A |
| 2021 | $6.17 Billion | $2.37 Million | -$23.21 Million | 2603.44x | N/A |
| 2022 | $199.87 Million | $1.88 Million | -$50.39 Million | 106.09x | N/A |
| 2023 | $30.81 Million | $50.00K | -$29.31 Million | 616.15x | N/A |
| 2024 | $55.09 Million | $225.00K | -$24.91 Million | 244.86x | N/A |
| 2025 | $26.98 Million | $400.00K | -$18.38 Million | 67.46x | N/A |
Competitor Companies of IBIO by Market Capitalization
Companies near iBio, Inc. Common Stock in the global market cap rankings as of July 7, 2026.
Key companies related to iBio, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #430 globally with a market cap of $64.60 Billion USD.
- UCB SA (BR:UCB): Ranked #543 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #567 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $529.59 |
| #430 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $649.81 |
| #543 | UCB SA | BR:UCB | $49.68 Billion | €254.40 |
| #567 | Argen-X | BR:ARGX | $47.14 Billion | €813.00 |
iBio, Inc. Common Stock Historical Marketcap From 2015 to 2025
Between 2015 and today, iBio, Inc. Common Stock's market cap moved from $62.96 Billion to $ 26.98 Million, with a yearly change of -54.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $26.98 Million | -51.02% |
| 2024 | $55.09 Million | +78.83% |
| 2023 | $30.81 Million | -84.59% |
| 2022 | $199.87 Million | -96.76% |
| 2021 | $6.17 Billion | -47.71% |
| 2020 | $11.81 Billion | +321.69% |
| 2019 | $2.80 Billion | -66.95% |
| 2018 | $8.47 Billion | -57.46% |
| 2017 | $19.91 Billion | -55.16% |
| 2016 | $44.41 Billion | -29.46% |
| 2015 | $62.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 7th, 2026 the market cap of iBio, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.96 Million USD |
| MoneyControl | $24.96 Million USD |
| MarketWatch | $24.96 Million USD |
| marketcap.company | $24.96 Million USD |
| Reuters | $24.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more